ARK Invest's position in CERS, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 11,197,791 | $21.7M | 0.30% | #41 |
| ARKG | 8,262,042 | $16.0M | 0.81% | #31 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | ARKK | Buy | Added | 344,578 | $1.0M |
| 2026-08-17 | ARKG | Buy | Added | 106,700 | $317K |
| 2026-08-14 | ARKK | Buy | Added | 66,263 | $197K |
| 2026-08-14 | ARKG | Buy | Added | 20,612 | $61K |
| 2026-08-13 | ARKK | Buy | Added | 54,561 | $155K |
| 2026-08-13 | ARKG | Buy | Added | 15,106 | $43K |
| 2026-08-12 | ARKK | Buy | Added | 71,585 | $194K |
| 2026-08-12 | ARKG | Buy | Added | 22,371 | $61K |
| 2026-08-11 | ARKK | Buy | Added | 195,574 | $502K |
| 2026-08-11 | ARKG | Buy | Added | 60,177 | $154K |
| 2026-08-10 | ARKK | Buy | Added | 66,950 | $169K |
| 2026-08-10 | ARKG | Buy | Added | 20,407 | $51K |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood…
See CERS's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open CERS on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.